-
Mashup Score: 0First-Line Nivolumab/Chemo Generates Long-Term Survival Benefits in Gastric/GEJ/Esophageal Cancer - 6 hour(s) ago
Frontline nivolumab plus chemotherapy elicited clinically meaningful long-term survival benefits vs chemotherapy alone in advanced gastric/GEJ cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
Frontline nivolumab/chemotherapy elicited long-term OS and PFS benefits vs chemotherapy alone at 5 years of follow-up in patients with advanced gastric cancer, GEJ cancer, and esophageal adenocarcinoma. @ASCO @YJanjigianMD @MSKCancerCenter #GI25 #esocsm https://t.co/4G9ahtI6gO https://t.co/7GdgvavNXK